<DOC>
	<DOCNO>NCT02472704</DOCNO>
	<brief_summary>Patients lymphocytic enteritis ( LE ) , HLA-DQ2/8+ , negative celiac serology clinical histological response gluten-free diet ( GFD ) fulfil diagnostic criterion coeliac disease ( CoD ) . At present remains unclear whether suffer coeliac gluten sensitivity ( CGS ) non-coeliac gluten sensitivity ( NCGS ) . There specific tissue marker CoD anti-transglutaminase deposit ( tTG ) intraepithelial lymphocytes express T-cell receptor ( TCR ) gamma/delta+ . Aim : To demonstrate existence CGS patient despite negative celiac serology . Methods : Double-blind randomize clinical trial gluten v placebo rechallenge 6 month patient LE GFD . Inclusion criterion : &gt; 18 year , initial presentation GI symptom , HLA-DQ2/8+ , negative celiac serology , good clinical histological response GFD . Patients randomise gluten ( 20 g/day ) placebo ( maltrodextrin ) ( identical powder sachet mixed meal ) . Clinical symptom analyse use visual analogue scale . Quality life ( GIQLI ) , adherence diet , serology , histological change include gamma/delta+ IEL tTG deposit evaluate .</brief_summary>
	<brief_title>Lymphocytic Enteritis Suspected Coeliac Disease : Gluten vs Placebo</brief_title>
	<detailed_description>Duodenal intraepithelial lymphocytosis ( lymphocytic enteritis , LE ) define normal villous architecture intraepithelial lymphocyte ( IEL ) &gt; 25/100 enterocytes . It frequent find present 2 % 5,4 % duodenal biopsy . LE secondary coeliac disease ( CoD ) minority patient , since may response inflammatory process gut . Other possible aetiology LE include infection ( Helicobacter Pylori ) , drug ( nonsteroidal anti-inflammatory acetylsalicylic acid ) autoimmune disease . Observational study establish CoD account 10 % 43 % case LD positive HLA-DQ2/8 undertaking exhaustive diagnostic work-up . These 'minor ' form CoD may similar clinical manifestation villous atrophy . However , patient 'minor ' CoD often negative celiac serology , fulfil present criterion diagnose CoD . In fact , use present diagnostic criterion include definition non-celiac gluten sensitivity ( NCGS ) . For diagnose NCGS necessary rule CoD mean negative serology -endomysial tissue transglutaminase IgA antibodies- duodenal biopsy absence villous atrophy gluten-containing diet . As accepted NCGS patient might LE . A recent systematic review NCGS reveal 44 % patient present HLA-DQ2/8 haplotype , suggest subgroup patient NCGS may actually belong spectrum CoD , author so-called 'coeliac lite ' disease . The gold-standard assay confirm NCGS require dietary elimination , follow double-blind , randomize , placebo-controlled food challenge . This procedure difficult adopt routinely clinical practice . To date two double-blind placebo-controlled dietary intervention patient presumptive NCGS publish . The first gluten v placebo rechallenge trial show patient receive gluten significantly abdominal symptom placebo ( 68 % vs 40 % ) . The second study investigate specific effect gluten dietary reduction fermentable , poorly absorb , short-chain carbohydrate ( FODMAPs ) subject believe NCGS , show symptomatic worsening gluten challenge compare placebo . Thus , evidence specific dose dependent effect gluten NCGS patient place diet low FODMAPs . It worth mention patient included trial HLA-DQ2/8 negative , positive normal duodenal biopsy ( Marsh 0 ) gluten contain diet . Besides , GFD show effective IBS-D patient negative CoD serology HLA-DQ2/8+ negative genetic study . The recent ESPGHAN guideline CoD diagnosis suggest case low-grade enteropathy ( include LE ) high γδ IEL count presence Ig A anti-tissue transglutaminase ( anti-TG2 ) deposit mucosa increase likelihood CoD . In contrast CoD , state NCGS increase T-cell receptor γδ IELs . However , parameter scarcely use rule CoD patient NCGS literature . The aim study demonstrate existence gluten sensitivity patient HLA-DQ2/8+ , LE negative celiac serology , present clinical histological response gluten-free diet ( GFD ) , use gluten vs placebo-controlled challenge . In addition , assess presence tissue marker CoD gluten challenge , thus confirm existence 'coeliac-lite ' disease .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Celiac Disease</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<criteria>1 . Giving write informed consent 2 . Patients age ≥18 year 3 . Histological diagnosis confirm lymphocytic enteritis ( LE ) 4 . Celiac genetic study ( HLADQ2 /or HLADQ8 positive ) 5 . Negative serology celiac disease 6 . Previous complete clinical histological response glutenfree diet 7 . Initial ( diagnosis ) GI symptom without extraintestinal manifestation . 8 . No previous study IEL cytometric pattern antiTG2 IgA subepithelial deposit . 1 . Patients unable adhere study visit schedule protocol requirement accord investigator . 2 . Participation clinical trial last 30 day , simultaneous participation trial prior participation study . 3 . Previous diagnosis glutensensitive enteropathy villous atrophy positive serology . 4 . Patients LE initial response gluten free diet time inclusion normal glutencontaining diet . 5 . Severe comorbidities . 6 . Drug alcohol abuse . 7 . Pregnancy breastfeed . At initial diagnosis , LE aetiologies , like nonsteroidal antiinflammatory drug intake , parasitic infection , Helicobacter pylorus infection , appropriately rule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>celiac disease</keyword>
	<keyword>lymphocytic enteritis</keyword>
	<keyword>non-celiac gluten sensitivity</keyword>
	<keyword>double-blind gluten rechallenge</keyword>
</DOC>